Delving into the Latest Updates on Beijing Rainforest Medical Technology Co., Ltd. with Synapse

Overview

（1）评估中国健康受试者单次、多次口服脑清智明片的安全性和耐受性，确定最大耐受剂量（MTD），为II期临床试验推荐合适的给药剂量（RP2D）。（2）考察脑清智明片单次、多次给药后在中国健康受试者体内的药代动力学（PK）特征。

[Translation]

(1) To evaluate the safety and tolerability of single and multiple oral administration of Naoqingzhiming tablets in healthy Chinese subjects, determine the maximum tolerated dose (MTD), and recommend an appropriate dosing dose (RP2D) for Phase II clinical trials. (2) To investigate the pharmacokinetic (PK) characteristics of Naoqingzhiming tablets in healthy Chinese subjects after single and multiple administration.

Start Date03 Aug 2020

Sponsor / Collaborator

Beijing Huayishennong Medicine Technology Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Rainforest Medical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Rainforest Medical Technology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Rainforest Medical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Rainforest Medical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data